Brokerages expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings of $0.12 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings, with estimates ranging from $0.01 to $0.23. Neurocrine Biosciences reported earnings per share of $0.07 during the same quarter last year, which would indicate a positive year over year growth rate of 71.4%. The firm is expected to issue its next earnings results on Tuesday, February 12th.

On average, analysts expect that Neurocrine Biosciences will report full year earnings of $0.19 per share for the current fiscal year, with EPS estimates ranging from $0.05 to $0.43. For the next fiscal year, analysts anticipate that the business will report earnings of $1.74 per share, with EPS estimates ranging from $0.73 to $2.78. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.04. The company had revenue of $151.80 million for the quarter, compared to analysts’ expectations of $151.51 million. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The firm’s quarterly revenue was up 149.7% compared to the same quarter last year. During the same period last year, the business posted ($0.13) earnings per share.

A number of equities research analysts have issued reports on NBIX shares. Leerink Swann started coverage on Neurocrine Biosciences in a research note on Monday, November 12th. They issued a “market perform” rating and a $110.00 target price on the stock. BidaskClub cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, September 15th. ValuEngine cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Morgan Stanley cut their target price on Neurocrine Biosciences from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Tuesday, November 6th. Finally, Cantor Fitzgerald began coverage on Neurocrine Biosciences in a research note on Friday, September 14th. They issued a “buy” rating and a $150.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $125.75.

In related news, Director Richard F. Pops sold 5,500 shares of Neurocrine Biosciences stock in a transaction dated Monday, October 29th. The stock was sold at an average price of $107.13, for a total transaction of $589,215.00. Following the transaction, the director now directly owns 37,759 shares of the company’s stock, valued at $4,045,121.67. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard F. Pops sold 4,123 shares of Neurocrine Biosciences stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $103.30, for a total value of $425,905.90. Following the transaction, the director now directly owns 33,636 shares in the company, valued at $3,474,598.80. The disclosure for this sale can be found here. Insiders have sold 33,623 shares of company stock worth $3,721,361 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. increased its stake in Neurocrine Biosciences by 643.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock worth $110,000 after purchasing an additional 972 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth about $127,000. TRUE Private Wealth Advisors acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth about $127,000. Signaturefd LLC boosted its position in Neurocrine Biosciences by 295.9% during the 3rd quarter. Signaturefd LLC now owns 1,338 shares of the company’s stock worth $165,000 after acquiring an additional 1,000 shares during the period. Finally, Financial Architects Inc boosted its position in Neurocrine Biosciences by 283.7% during the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock worth $170,000 after acquiring an additional 1,024 shares during the period. 98.88% of the stock is currently owned by hedge funds and other institutional investors.

NBIX stock opened at $89.98 on Friday. The firm has a market capitalization of $8.16 billion, a price-to-earnings ratio of -55.54, a P/E/G ratio of 23.02 and a beta of 0.94. Neurocrine Biosciences has a 1 year low of $67.32 and a 1 year high of $126.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

See Also: Bond

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.